Finance

Lists
EW:NYSE
Edwards Lifesciences Corp
$84.37
-2.77%
(-2.40) 1D
$84.37
0.00% (0.00)
After hours
Closed: Sep 11, 4:00:06 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for EW...
Open
$87.51
High
$87.76
Low
$83.81
Mkt. cap
48.63B
Avg. vol.
2.99M
Volume
3.80M
P/E ratio
48.81
52-wk high
$96.29
52-wk low
$72.30
EPS
$1.73
Beta
0.85
Shares outstanding
576.40M
No. of employees
16K
Open
$87.51
High
$87.76
Low
$83.81
Mkt. cap
48.63B
Avg. vol.
2.99M
Volume
3.80M
P/E ratio
48.81
52-wk high
$96.29
52-wk low
$72.30
EPS
$1.73
Beta
0.85
Shares outstanding
576.40M
No. of employees
16K
News stories
From web sources and news partners
An error has occurred
Profile
Edwards Lifesciences Corporation is an American medical technology company headquartered in Irvine, California, specializing in tissue heart valves and transcatheter technologies for the treatment of structural heart disease. The company has manufacturing facilities at the Irvine headquarters, as well as in Draper, Utah; Costa Rica; Singapore; and Limerick, Ireland. The company is also constructing a manufacturing plant in Moncada, near Valencia, Spain, with a €150 million investment. Production is scheduled to begin in 2027. Wikipedia
About Edwards Lifesciences Corp
CEO-
Employees16K
Founded1958
HeadquartersIrvine, California, United States
SectorMedical device
Analyst ratings
Based on 18 analysts giving stock ratings to EW in the past 3 months
Strong buy
Buy
15
Hold
3
Sell
0
12-month forecast
Based on 18 Wall Street analysts offering 12 month price targets for EW in the last 3 months.
Highest
Current $84.37
$110.00 (+30.38%)
Average
$103.06 (+22.15%)
Lowest
$85.00 (+0.75%)
Analyst
Recommendation
Action
Price target
Projected
Date
Matthew Taylor
Jefferies
Buy
Maintained
$105.00
+24.5%
09/11/2026
Marie Thibault
BTIG
Buy
Maintained
$110.00
+30.4%
09/10/2026
Brandon Vazquez
William Blair
Buy
Maintained
-
-
09/10/2026
Joanne Wuensch
Citi
Buy
Maintained
$110.00
+30.4%
09/10/2026
William Plovanic
Canaccord Genuity
Hold
Maintained
$85.00
+0.7%
08/03/2026
Robbie Marcus
J.P. Morgan
Buy
Maintained
$105.00
+24.5%
07/28/2026
Patrick Wood
UBS
Buy
Upgraded
$110.00
+30.4%
07/28/2026
Rick Wise
Stifel Nicolaus
Buy
Maintained
$110.00
+30.4%
07/24/2026
Suraj Kalia
Oppenheimer
Hold
Maintained
-
-
07/24/2026
Richard Newitter
Truist Financial
Hold
Reiterated
$95.00
+12.6%
07/24/2026
Adam Maeder
Piper Sandler
Buy
Reiterated
$101.00
+19.7%
07/24/2026
Shagun Singh Chadha
RBC Capital
Buy
Reiterated
$110.00
+30.4%
07/23/2026
Mike Kratky
Leerink Partners
Buy
Upgraded
$101.00
+19.7%
07/24/2026
Travis Steed
Bank of America Securities
Buy
Maintained
$100.00
+18.5%
07/21/2026
Josh Jennings
TD Cowen
Buy
Reiterated
$104.00
+23.3%
07/23/2026
Anthony Petrone
Mizuho Securities
Buy
Maintained
$105.00
+24.5%
07/15/2026
Vijay Kumar
Evercore ISI
Buy
Maintained
$100.00
+18.5%
07/06/2026
David Roman
Goldman Sachs
Buy
Maintained
$98.00
+16.2%
06/15/2026
Krish Sankar
TD Cowen
Buy
Reiterated
$104.00
+23.3%
06/02/2026
David Toung
Argus Research
Buy
Maintained
-
-
05/21/2026
David Rescott
Robert W. Baird
Hold
Maintained
$87.00
+3.1%
04/24/2026
Matt Miksic
Barclays
Buy
Maintained
$110.00
+30.4%
04/24/2026
Michael Polark
Wolfe Research
Buy
Upgraded
$92.00
+9%
04/01/2026
Danielle Antalffy
UBS
Hold
Maintained
$90.00
+6.7%
02/12/2026
Larry Biegelsen
Wells Fargo
Buy
Reiterated
$100.00
+18.5%
02/11/2026
Last report
Jul 23, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
$0.78 / $0.74
+5.11%beat
Revenue / Est. (USD)
1.74B / 1.70B
+2.44%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
-
-
-
-
Operating expense
-
-
-
-
Total operating expenses
-
-
-
-
Operating income
-
-
-
-
Other non operating income
-
-
-
-
EBT including unusual items
-
-
-
-
EBT excluding unusual items
-
-
-
-
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-
-
-
-
Net profit margin
18.74%
5.81%
23.09%
13.89%
Earnings per share
-
-
-
-
Interest and investment income
-
-
-
-
Interest expense
-
-
-
-
Net interest expenses
-
-
-
-
Depreciation and amortization charges
-
-
-
-
EBITDA
-
-
-
-
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google apps